Revvity
NYSE: RVTY
Stock price
117.5 USD
(+0%) TODAY
Financial Performance
5Y price score: (48)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 121.1%
US$ Per
Share
By default your notes are visible only to you.
81.2
52-week range
118.3
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
4.2 %
Dividend Yield TTM
0.2 %
Market cap $
$ 13,108
Price / Earnings TTM
56
Price / Book TTM
1.8
PEG TTM
(4.1)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
29.5 %
(35.1) %
121.1 %
Free cash flow per share growth
1.8 %
(39.3) %
97.6 %
Earnings per share growth
(13.7) %
(68) %
10.9 %
Founded: 1,937
Employees: 11,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Aug 4, 2026)
1) Strong Financial Performance and Guidance Update
- Revvity reported Q2 2026 total revenue of $711 million, achieving 3% organic growth, exceeding expectations.
- Adjusted EPS was $1.41, surpassing guidance due to operational performance and $16 million in tariff refunds.
- Full-year organic growth guidance raised to 4% to 5% from 3% to 4%; adjusted operating margins expected at 28.7%.
- Adjusted EPS guidance increased to $5.30 to $5.40, reflecting improved revenue and margin outlook.
2) Segment Performance Highlights
- Diagnostics segment grew 11% organically, driven by strong performance in reproductive health and immunodiagnostics.
- Life Sciences segment faced a 3% organic decline, primarily due to a 20% drop in Signals software revenue; however, reagents and instruments showed positive growth.
- High-content screening instruments, particularly the Opera Phenix OptIQ, saw double-digit growth, indicating strong demand in AI-driven workflows.
3) Strategic Initiatives and Market Positioning
- Revvity is divesting its China immunodiagnostics business, with a definitive agreement signed, expected to close by the end of 2027.
- The company is focusing on enhancing its Signals software capabilities, integrating AI functionalities to improve customer workflows.
- New initiatives like Signals for Startups aim to broaden access to Revvity's platform for emerging biotech firms.
4) Operational Efficiency and Cash Flow
- Strong cash flow generation of $184 million in Q2, with a 117% conversion rate of adjusted net income.
- The company retired a EUR 500 million note, targeting a gross leverage ratio below 3x by year-end.
- Continued investment in operational efficiency and strategic initiatives is expected to enhance long-term performance.
5) Market Outlook and Challenges
- Revvity is optimistic about the second half of 2026, citing improved conditions in pharma and biotech markets.
- The company anticipates continued demand for AI-related tools, although the full impact of these trends on revenue is still developing.
- There are challenges related to the timing of instrument deliveries and software contract renewals, which may affect short-term performance.
Bottom line: Revvity's strong Q2 performance and raised guidance reflect a resilient business model, particularly in Diagnostics and high-content screening, positioning the company well to capitalize on emerging AI-driven opportunities in preclinical research.
Annual Reports, Presentations And IR Contacts
Go to the websiteRevvity — Financial Overview, Stock Price, Market Cap
Revvity is a company. Founded in 1937. As of August 14, 2026, the company's market capitalization is $13108300000 with a current stock price of $117.50.